Abstract

While immune checkpoint inhibitors (ICIs) have transformed standards of care and drastically improved patient prognoses in several malignant diseases, a range of immune related adverse events (irAEs) from ICIs have been observed. This case series describes the clinical course of three patients with unusual immune checkpoint-inhibitor (ICI) induced toxicities. These three patients developed carpal tunnel syndrome (CTS) while on ICI therapy. The first patient was a 79 year-old male who received neo-adjuvant chemo-immunotherapy and adjuvant immunotherapy (atezolizumab) for stage II-B lung adenocarcinoma, the second patient was a 70 year-old female who received immunotherapy only (nivolumab) for stage IV renal cell carcinoma and the third patient was a 71 year-old male who received adjuvant immunotherapy (nivolumab) for stage 2-A melanoma. The patients developed carpal tunnel syndrome with severe neuropathy as a result of therapy. All patients had complete symptomatic relief when treated with either corticosteroids or intravenous immunoglobulins for CTS.

Keywords: Atezolizumab, Nivolumab, Carpal tunnel syndrome, Lung Carcinoma, Renal Cell Carcinoma, Immune Checkpoint Inhibitors (ICIs), Immune Related Adverse Events (irAEs), Israel

Downloads

Download data is not yet available.
 How to Cite
Shalata, W., Yakobson, A., Massalha, I., Grinberg, R. D., Goldstein, I. M., Gibbs, R., … Rouvinov, K. (2020). Carpal Tunnel Syndrome as an Unusual Immune Checkpoint Inhibitor Adverse Effect: A Case Series and Review of the Literature. International Journal of Innovative Research in Medical Science, 5(11), 550–553. https://doi.org/10.23958/ijirms/vol05-i11/981

Copyrights & License